| Drug Name | ***0156 |
| Description |
Death receptor 5 (DR5), also known as TRAIL receptor 2 (TRAILR2) is a cell surface receptor that binds TRAIL and mediates apoptosis. An antibody-drug conjugate consisting of an antibody targeting DR5 linked to monomethyl dolastatin 10 (MMAD, a tubulin inhibitor) is in preclinical development. These preclinical data demonstrate that the product is a potential cancer therapeutic agent. |
| Target | DR5; Tubulin |
| Drug Modality | Antibody-Drug Conjugate |
| Indication | Cancer |
| Product Category | Apoptosis Inducer |
| Mechanism of Action | Targeting DR5 and inducing apoptosis of tumor cells |
| Status | Preclinical |
| Patent | Granted |
We look forward to hearing from you.
Protheragen's business is growing rapidly after founded in New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.
 |
Protheragen Inc. |
 |
Quick Links |